✉news HealthMedicine first seen 8 h ago, last 1 h ago, peak #22
Retatrutide Shows Record Weight Loss in Type 2 Diabetes Trial
Original: Triple Agonist Retatrutide Pushes Weight Loss to New Levels in Type 2 Diabetes
Eli Lilly's triple agonist retatrutide has been reported to push weight loss to new levels among patients with type 2 diabetes, according to Inside Precision Medicine. The drug, which targets three hormone receptors, is being studied as one of the most powerful obesity and diabetes treatments in development, extending gains seen with tirzepatide and semaglutide.
Why now: New results for an experimental obesity and diabetes drug are generating attention amid huge demand for GLP-1 therapies.
Eli Lillyretatrutidetype 2 diabetes
Rank over time, top of the chart is #1. 6 snapshots from 8 h ago to 1 h ago.
Evidence
- Triple Agonist Retatrutide Pushes Weight Loss to New Levels in Type 2 Diabetes · Inside Precision Medicine
API: https://socialmediatrends-api.osmike.com/v1/trends/443777